Hot Life Science Investor Mandate 1: Hedge Fund has Biotech Focus, Large AUM

10 Oct

A biotech-focused Hedge Fund based in the Western US currently manages nearly $1b in assets under an evergreen fund structure, and is currently looking for investment opportunities across the United States and Europe. They have no set mandate for the number of companies they plan to allocate to over the next 6-9 months, and their investment size varies by case.

The fund is currently only looking for companies developing therapeutics, and is agnostic in terms of therapeutic area and target. They prefer to invest in companies with assets in later stages of clinical trials – typically in Phases II and III.

Fundamentally driven, they have a strong preference for companies that have gone public or are considering going public in the near future. Although the firm does prefer later stage companies, they do not require that the company is currently generating revenue. In terms of management team, the fund is looking for experienced management to be in place. However, they do not require that the current management be the long-term team for the company.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: